vs
Fidelity National Financial, Inc.（FNF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Fidelity National Financial, Inc.的1.4倍（$772.1M vs $544.0M），Revvity净利率更高（12.7% vs -21.5%，领先34.2%），Fidelity National Financial, Inc.同比增速更快（10.3% vs 5.9%），过去两年Fidelity National Financial, Inc.的营收复合增速更高（13.7% vs 9.0%）
富达国民金融是美国财富500强企业，主要面向房地产与抵押贷款行业提供产权保险及交割服务，2019年其产权及房地产业务相关年度营收约为84.69亿美元，是全球领先的产权保险服务供应商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FNF vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$544.0M
营收增速更快
FNF
高出4.5%
5.9%
净利率更高
RVTY
高出34.2%
-21.5%
两年增速更快
FNF
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $544.0M | $772.1M |
| 净利润 | $-117.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 82.9% | 14.5% |
| 净利率 | -21.5% | 12.7% |
| 营收同比 | 10.3% | 5.9% |
| 净利润同比 | -126.0% | 3.9% |
| 每股收益（稀释后） | $-0.44 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNFRVTY
| Q4 25 | $544.0M | $772.1M | ||
| Q3 25 | $553.0M | $698.9M | ||
| Q2 25 | $547.0M | $720.3M | ||
| Q1 25 | $455.0M | $664.8M | ||
| Q4 24 | $493.0M | $729.4M | ||
| Q3 24 | $506.0M | $684.0M | ||
| Q2 24 | $504.0M | $691.7M | ||
| Q1 24 | $421.0M | $649.9M |
净利润FNFRVTY
| Q4 25 | $-117.0M | $98.4M | ||
| Q3 25 | $358.0M | $46.7M | ||
| Q2 25 | $278.0M | $53.9M | ||
| Q1 25 | $83.0M | $42.2M | ||
| Q4 24 | $450.0M | $94.6M | ||
| Q3 24 | $266.0M | $94.4M | ||
| Q2 24 | $306.0M | $55.4M | ||
| Q1 24 | $248.0M | $26.0M |
毛利率FNFRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FNFRVTY
| Q4 25 | 82.9% | 14.5% | ||
| Q3 25 | 81.9% | 11.7% | ||
| Q2 25 | 69.8% | 12.6% | ||
| Q1 25 | 24.4% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 61.9% | 14.3% | ||
| Q2 24 | 90.9% | 12.4% | ||
| Q1 24 | 78.6% | 6.8% |
净利率FNFRVTY
| Q4 25 | -21.5% | 12.7% | ||
| Q3 25 | 64.7% | 6.7% | ||
| Q2 25 | 50.8% | 7.5% | ||
| Q1 25 | 18.2% | 6.4% | ||
| Q4 24 | 91.3% | 13.0% | ||
| Q3 24 | 52.6% | 13.8% | ||
| Q2 24 | 60.7% | 8.0% | ||
| Q1 24 | 58.9% | 4.0% |
每股收益（稀释后）FNFRVTY
| Q4 25 | $-0.44 | $0.86 | ||
| Q3 25 | $1.33 | $0.40 | ||
| Q2 25 | $1.02 | $0.46 | ||
| Q1 25 | $0.30 | $0.35 | ||
| Q4 24 | $1.65 | $0.77 | ||
| Q3 24 | $0.97 | $0.77 | ||
| Q2 24 | $1.12 | $0.45 | ||
| Q1 24 | $0.91 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.6B | $919.9M |
| 总债务越低越好 | $4.4B | — |
| 股东权益账面价值 | $7.4B | $7.3B |
| 总资产 | $109.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.59× | — |
8季度趋势，按日历期对齐
现金及短期投资FNFRVTY
| Q4 25 | $2.6B | $919.9M | ||
| Q3 25 | $3.5B | $931.4M | ||
| Q2 25 | $3.3B | $991.8M | ||
| Q1 25 | $4.5B | $1.1B | ||
| Q4 24 | $3.5B | $1.2B | ||
| Q3 24 | $5.0B | $1.2B | ||
| Q2 24 | $4.9B | $2.0B | ||
| Q1 24 | $3.5B | $1.7B |
总债务FNFRVTY
| Q4 25 | $4.4B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.2B | — | ||
| Q1 24 | $3.9B | — |
股东权益FNFRVTY
| Q4 25 | $7.4B | $7.3B | ||
| Q3 25 | $8.4B | $7.4B | ||
| Q2 25 | $7.9B | $7.6B | ||
| Q1 25 | $7.9B | $7.6B | ||
| Q4 24 | $7.8B | $7.7B | ||
| Q3 24 | $8.1B | $7.9B | ||
| Q2 24 | $7.3B | $7.9B | ||
| Q1 24 | $7.1B | $7.8B |
总资产FNFRVTY
| Q4 25 | $109.0B | $12.2B | ||
| Q3 25 | $106.6B | $12.1B | ||
| Q2 25 | $102.3B | $12.4B | ||
| Q1 25 | $98.2B | $12.4B | ||
| Q4 24 | $95.4B | $12.4B | ||
| Q3 24 | $94.7B | $12.8B | ||
| Q2 24 | $88.8B | $13.4B | ||
| Q1 24 | $84.5B | $13.4B |
负债/权益比FNFRVTY
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.56× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.58× | — | ||
| Q1 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5B | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FNFRVTY
| Q4 25 | $1.5B | $182.0M | ||
| Q3 25 | $1.3B | $138.5M | ||
| Q2 25 | $1.9B | $134.3M | ||
| Q1 25 | $1.1B | $128.2M | ||
| Q4 24 | $1.5B | $174.2M | ||
| Q3 24 | $2.4B | $147.9M | ||
| Q2 24 | $1.4B | $158.6M | ||
| Q1 24 | $1.6B | $147.6M |
自由现金流FNFRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率FNFRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度FNFRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率FNFRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 3.66× | 2.97× | ||
| Q2 25 | 6.82× | 2.49× | ||
| Q1 25 | 13.43× | 3.03× | ||
| Q4 24 | 3.32× | 1.84× | ||
| Q3 24 | 8.89× | 1.57× | ||
| Q2 24 | 4.45× | 2.87× | ||
| Q1 24 | 6.42× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
